Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer.

TitleThymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer.
Publication TypeJournal Article
Year of Publication1996
AuthorsBao L, Loda M, Janmey PA, Stewart R, Anand-Apte B, Zetter BR
JournalNat Med
Date Published1996 Dec
KeywordsActins, Amino Acid Sequence, Animals, Base Sequence, Biomarkers, Tumor, Carcinoma, Cell Movement, Cloning, Molecular, Gene Expression Regulation, Neoplastic, Humans, Hyperplasia, Male, Molecular Sequence Data, Neoplasm Metastasis, Organ Specificity, Prostate, Prostatic Neoplasms, Rats, Recombinant Fusion Proteins, RNA, Antisense, RNA, Messenger, RNA, Neoplasm, Thymosin, Tumor Cells, Cultured

The Dunning rat prostatic carcinoma is a model system where cell motility closely correlates with the metastatic phenotype. We have identified a novel gene, upregulated in the highly motile and metastatic Dunning cancer cell lines, that represents a new member of the thymosin-beta family, thymosin beta 15. Transfection of antisense thymosin beta 15 constructs into rat prostatic carcinoma cells demonstrates that this molecule positively regulates cell motility, a critical component of the metastatic pathway. Thymosin beta 15 levels are elevated in human prostate cancer and correlate positively with the Gleason tumor grade. Thymosin beta 15 may represent a potential new biochemical marker for human prostate cancer progression.

Alternate JournalNat Med
PubMed ID8946830
Grant ListCA 37393 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700